News | July 01, 2009

Study Evaluates Safety, Tolerability of Drug for Acute Decompensated Heart Failure

July 1, 2009 – Cardioxyl Pharmaceuticals Inc. announced today the initiation of a phase I/IIa dose-escalation study of lead drug candidate, CXL-1020, for the treatment of acute decompensated heart failure (ADHF).

The study has already begun enrollment, and researchers dosed the first patient in June 2009. The study will evaluate the safety and tolerability of CXL-1020 and its specific effects on noninvasive hemodynamic parameters in patients with chronic stable heart failure. It will also evaluate the pharmacokinetics of CXL-1020.

The company hopes the drug will provide a safe and effective therapy to enhance both diastolic and systolic function while concomitantly reducing vascular resistance. CXL-1020 is a novel, first-in-class, small molecule nitroxyl (HNO) donor therapeutic drug candidate.

“In preclinical trials, CXL-1020 has exhibited a very attractive suite of physiologic effects in canine models of heart failure,” said Wilson S. Colucci, M.D., Boston University Medical Center Cardiovascular Center and Steering Committee chair. “We look forward to evaluating the safety and tolerability, as well as the hemodynamic effects of CXL-1020 in this dose-escalation study.”

For more information: www.cardioxyl.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init